Patents Assigned to Horizon Orphan LLC
  • ADO-resistant cysteamine analogs and uses thereof
    Patent number: 11505550
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: November 22, 2022
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Delayed release cysteamine bead formulation, and methods of making and using same
    Patent number: 11090279
    Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: August 17, 2021
    Assignee: Horizon Orphan LLC
    Inventors: Kathlene Powell, Ramesh Muttavarapu, Ranjan Dohil
  • Topical use of levofloxacin for reducing lung inflammation
    Patent number: 11020481
    Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 1, 2021
    Assignee: Horizon Orphan LLC
    Inventors: Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
  • Aerosolized fluoroquinolones and uses thereof
    Patent number: 10987357
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: April 27, 2021
    Assignee: Horizon Orphan, LLC
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Methods for storing cysteamine formulations and related methods of treatment
    Patent number: 10905662
    Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: February 2, 2021
    Assignee: Horizon Orphan LLC
    Inventors: Michael Desjardin, Mark Johnson
  • ADO-resistant cysteamine analogs and uses thereof
    Patent number: 10906904
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 2, 2021
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Use of aerosolized levofloxacin for treating cystic fibrosis
    Patent number: 10792289
    Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 6, 2020
    Assignee: Horizon Orphan LLC
    Inventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 10722519
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 28, 2020
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • Methods for storing Cysteamine formulations and related methods of treatment
    Patent number: 10548859
    Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 4, 2020
    Assignee: Horizon Orphan LLC
    Inventors: Michael Desjardin, Mark Johnson
  • Methods for storing cysteamine formulations and related methods of treatment
    Patent number: 10328037
    Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 25, 2019
    Assignee: Horizon Orphan LLC
    Inventors: Michael Desjardin, Mark Johnson
  • Fucosidase inhibitors
    Patent number: 10308607
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 4, 2019
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • Use of aerosolized levofloxacin for treating cystic fibrosis
    Patent number: 10231975
    Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 19, 2019
    Assignee: Horizon Orphan LLC
    Inventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
  • FUCOSIDASE INHIBITORS
    Publication number: 20190077756
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Application
    Filed: March 30, 2018
    Publication date: March 14, 2019
    Applicant: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 10149854
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 11, 2018
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • Methods for storing cysteamine formulations and related methods of treatment
    Patent number: 10143665
    Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 4, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Michael DesJardin, Mark Johnson
  • Fucosidase inhibitors
    Patent number: 9951013
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: April 24, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
    Patent number: 9879064
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 30, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 9717738
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 1, 2017
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • Use of aerosolized levofloxacin for treating cystic fibrosis
    Patent number: 9700564
    Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: July 11, 2017
    Assignee: Horizon Orphan LLC
    Inventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya